VOLUME 40 1991

SUBJECT INDEX

Abstinence, 995
Acetaminophen, 513
Acetylcholine, 763
Acetylcholinesterase, 929
Acids, 523
Acrosome reaction, 609
Actin, 617
Active avoidance, 61
Activity pattern analyses, 959
Addiction, 887
Adenosine, 33
Adenosine A1 receptors, 33
Adenosine receptor, 811
Adenylate cyclase, 565
Adrenal medulla, 593
Adrenalectomy, 861
α-Adrenoceptor antagonist, 709
Affect, 229, 443
Aggression, 835
Aging, 949
Agoraphobia, 959
AIDS, 695
Akinesia, 261
Alcohol, 867
Alcohol drinking, 923
Alcohol preference, 923
Alcohol sensitivity, 409
Aldosterone, 861
Aliesterase, 929
Alpha-1 adrenoceptors, 125
Alveolar macrophages, 643
Ames test, 541
Amide compound, 465
Amino acid diet, 83
Aminoalkylindole analogs, 471
Aminooxyacetic acid, 287
AMPA, 21
Amphetamine, 21, 181, 881, 915, 983
d-Amphetamine, 215, 317, 775
Analgesia, 197, 297, 317, 479
Analysis, 465
Anesthesia, 767
Anhedonia, 1001
Animal model of CNS plasticity, 367
Anorectic, 75
Anorexia, 53, 83, 875
ANP, 61
Antagonist, 893
Anterior pituitary, 603
Anticholinesterase, 17
Anticonflict, 787, 795
Anticonvulsant effect, 581
Antidepressant, 69
Antiemetic, 695, 1033
Antimuscarinic, 345
Antinociception, 479, 509, 581
Antipsychotic, 89
Anxiety, 7, 819
Anxiolytic, 89, 733, 739
Aphrodisiac, 221
Apomorphine, 317
Approach response, 323
Arachidonic acid, 559
Arecoline, 763
Arousal, 215, 229
Atrial natriuretic peptide, 237
Atrium, 345
Atropine, 745
Attack, 781
Autoradiography, 339
Autoreceptors, 901
Autotomy, 301
Avoidance behavior, 237

Balanced-placebo design, 115
Barbiturate synergism, 541
Bed nucleus of the stria terminalis, 977
Behavior, 279
Behavioral stimulation, 291
Behavioral thermoregulation, 709
Benzodiazepine, 109, 429, 581
Beta-endorphin, 229, 449
Beta-oxidation, 523
Bicuculline, 109, 287
Bicyclic analogs, 471
Bioassay, 629
Bioavailability of THC, 497
Biodistribution, 503
Blood pressure, 701
Blood-brain barrier, 771
Body temperature, 129, 157, 249, 581, 709
Brain, 767
Brain calcium, 423
Brain reward, 571
Brain stimulation reward, 273
Brain temperature, 33
(−)-5′-Bromo-Δ^8-THC, 509
Buspirone, 733, 787
Butt length, 657

Caffeine, 21, 121, 811, 847
Caffeine pharmacokinetics, 723
Calcium-calmodulin-dependent-catecholamine synthesis, 423
Calcium channels, 949
Cancer chemotherapy, 695
Cannabichromene, 533
Cannabidiol, 517, 523, 533, 541, 581, 609, 701
Cannabielsoin, 541
Cannabigerol, 533
Cannabinoid, 461, 479, 491, 517, 547, 553, 571, 593, 609, 617, 637, 695
Cannabinoid pharmacological profile, 471
Cannabinoid receptor, 565
Cannabinol, 533, 609
Cannabis, 97, 487, 517, 571, 671, 683, 689, 701
Cannabis in the Bible, 461
Capillary column GC, 517
Capsaicin, 163
Capsules of CBD and sesame oil, 517
Carbohydrate, 861
β-Carbolines, 329
Carbon monoxide, 651, 657
Cardiovascular responses, 157
Cat, 345, 367, 533
Catalepsy, 559, 829, 1001
Cataleptogenic effects, 465
Catalytic hydrogenation, 461
Catecholamine, 593, 937
Central ambulations, 959
Cerebral metabolic activity, 339
CGS 10746B, 255
CGS 19755, 767, 893
ChAT, 7
Chemical analyses, 629
Chemical kindling, 329
Chin rub, 983
Chiral synthesis, 487
Chloride flux, 409
Chlorocitrate, 75
Chlorpromazine, 129, 775
Cholinergic, 763
Chorea, 701
Chronic cannulation, 449
Chronic marijuana amoke, 643
Chronic stress, 283
Cigarette, 177
Cigarette brands, 177
Cigarette smoke, 453
Cigarette yield, 139
Classical conditioning, 987
Cliff avoidance, 241
Cocaine, 41, 133, 157, 273, 387, 625, 807, 841, 941, 959, 969
Coffee, 847
Cognitive expectancies, 115
Cognitive functioning, 683
Cold stress, 423
Conditioned place preference, 443, 987
Conditioned place preference/aversion, 255
Conditioned response, 983
Conditioned suppression of drinking, 787, 795
Conditioned taste aversion, 717, 983
Conditioned tolerance, 53
Conformational analysis, 479
Conjugates, 523
Controlled clinical trial, 701
Convulsions, 157, 297, 329
Corpus striatum, 399
Corticosterone, 53, 409, 861
Corticotropin-releasing factor, 717
Cortisol, 229
Cotinine, 177
p-Coumaroyltyramine, 465
CPP, 893
Crickets, 887
Cross-sectional study, 139, 907
Cyclic AMP, 565
Cyclohexyladenosine, 811
Cyclo(leucyl-glycyl), 881
Cyclopentyladenosine (CPA), 33
Cyproheptadine, 433
Cytochrome P-450, 541
Cytoskeleton, 617
Cytotoxins, 629

D1 receptor, 103
D2 receptor, 103
D_1 dopamine receptor, 829
D_1 receptors, 133
D_2 receptors, 133
DA, 7, 571

Daily marijuana smoking, 691
Dapiprazol, 125
Day-old chicks, 173
Deafferentation pain, 301
Defecation, 443
Defense, 781
Defensive behavior, 751, 819
Delta-9-tetrahydrocannabinol, 593, 603, 609, 617, 643, 651, 677
Delta-9-THC, 581
Desensitization, 565
Determination, 465
Deuterium NMR, 553
Dexamethasone, 717
Dextromethorphan, 381
Dextrorphan, 381
Diamine oxidase, 359
Diastereomeric solute-solute interaction, 491
Diazepam, 109, 739, 787
Diazepam and β-carbolines, 335
Diethyl ether, 767
Diltiazem, 801
Dimethylheptyl side chain, 471
Diphenhydramine, 191
Discrimination, 745
Dog, 17, 523
Domestication, 751
Domperidone, 209
DOPAC, 7
Dopamine, 21, 133, 181, 191, 241, 255, 305, 387, 571, 603, 841, 915, 923, 959, 969, 1001
Dopamine receptor supersensitivity, 881
Dopamine release, 399, 587
Dopamine transport, 387
Dopamine turnover, 399
Dopamine uptake, 399
Dopaminergic receptors, 157
Dorsal hippocampus, 169, 181
Dorsal raphe nucleus, 1001
Dose-response, 929
Double-blind, 701
Drinking, 125, 923
Dronabinol, 695
Drug abuse, 381, 571
Drug addiction, 571
Drug discrimination, 757
Drug interactions, 121
Drug-membrane interactions, 553
Drugs of abuse, 273

Eating, 867
Eating behavior, 185
EEG, 97, 215, 351
Efficacy, 701
Egg jelly coat, 609
Electrical stimulation, 323
Electrochemistry, 571
Electroencephalogram, 771
Electron microscopy, 671
Electroshock, 297
Eledoisin, 977
Emesis, 345
Emotional stress, 287
Enantiomeric purity, 491
β-Endorphin, 79
Energy expenditure, 203
Enkephalin, 771
Enzyme analysis, 847
Epoxide-diol pathway, 523
1*S*,2*R*-Epoxy intermediate, 541
Escape, 835
Escape response, 323
Estradiol, 603
Estrogen-induced LH release, 335
Ethanol, 767, 923
Ethanol tolerance, 261
Ethological analysis, 847
N-Ethyl-carboxamido-adenosine (NECA), 33
Event-related potentials, 683
Ex-smokers, 995
Excitatory amino acids, 949
Exploration, 169
Exploratory behavior, 7
Extract of Ginkgo biloba (EGb 761), 367

(−)-5′^{18}F-Δ^8-THC, 503
Fat, 861
Fear, 819
Feeding behavior, 83, 853, 861
Feeding pattern, 867
Felbamate, 109
Fenfluramine, 267
Fertilization, 609
Feruloyltyramine, 465
Fetus, 97
FG-7142, 169
Fine movements, 959
Fixed-interval, 775
Fixed-interval schedule, 1
Flavor preference, 717
(−)-5′-Fluoro-Δ^8-THC, 509
(−)-11-Fluoro-Δ^8-THC, 509
Fluoxetine, 311
cis-Flupenthixol, 317
Flurazepam, 581
Focal interictal activity, 351
Food intake, 27, 75, 133, 185
Formalin test, 197, 317
Freely moving rat, 959, 969
Frontal cortex, 7
Fullness, 185
Functional disability, 701
Fungicide, 775
Furosemide, 163

G protein, 559, 565, 1053
GABA, 329, 429
GABAergic mechanism, 287
GABA receptor, 109
GABOB, 359
Gamma-aminobutyric acid, 581
Gamma-butyrolactone (γ-BL), 969
Gas chromatography/mass spectroscopy (GC/MS), 517, 701
Gas exchange, 17
Gastric emptying, 75
Gender, 203, 229
Gene expression, 617
Genetic model, 409
Genital, 151
Gepirone, 795
Gerbil, 533
Glucose metabolism, 625
Glucosides, 523
Glucuronides, 523
L-Glutamate, 767
Glutamate receptor, 949
Glycosylation, 565
Golgi, 671
Gonadal hormones, 901
Guinea pig, 129, 533, 541
Guinea pig isolated ileum, 581

Half-life of CBD, 517
Haloperidol, 41, 399, 1001
Halothane, 767
Hamster, 533
Handling habituation, 409
Hashish smoking behavior, 115
Heart rate effects, 691
Heat loss, 709
Heat production, 709
Hedonics, 185
Heroin, 339, 841
Hexahydrocannabinol, 533, 553
5-HIAA, 7, 267
"High", 657
High pressure, 305
Hindlimb grip response, 241
Hippocampus, 7, 345, 671
Histamine, 191
Histamine H1 receptor antagonist, 191
Homovanillic acid, 191, 587
Hooded rats, 215
5-HT, 7, 267, 1041
5-HT_1, 1009
5-HT_{1A}, 221, 1019
5-HT_{1C}, 1019
5-HT_2, 1009, 1019
5-HT_3, 1009
5-HT_4, 1009
5-HT_{1B} agonists, 279
5-HT_{1A} receptors, 1041
5-HT_3 receptor, 151, 1033
5-HT serotonergic receptors, 751
Hu-210, 461
Human, 691, 835
Hunger, 185, 867
Huntington's chorea, 701
Huntington's disease, 701
6-Hydroxydopamine, 399, 923
9α-Hydroxy-hexahydrocannabinol, 479
9β-Hydroxy-hexahydrocannabinol, 479
5-Hydroxyindoleacetic acid, 587
Hydroxylation, 523
2-Hydroxyputrescine, 359
5-Hydroxytryptamine, 301
Hyperbaric conditions, 197
Hyperphagia, 901
Hypothalamus, 853
Hypothermia, 129, 261, 465, 541, 581, 901
Hypoxia, 1

Ibotenic acid, 181
Ibotenic acid lesion, 169
ICI D7114 metabolite, 249
ICSS, 571
Ileum, 345
Illumination, 215
Imbalanced diet, 83
Inactivity, 69
Inhalation, 637
Interaction, 625
Intracerebroventricular, 807
Intraperitoneal, 449
Intrathecal, 449
In vivo electrochemistry (voltammetry) presynaptic release, 969
In vivo voltammetry (electrochemistry) ambulations, 959
(−)-2-Iodo-Δ^8-THC, 509
(−)-5′-Iodo-Δ^8-THC, 509
Ion trap MS, 517
Ionophores, 609
Iprindole, 881

Ipsapirone, 739
Isolation, 279, 465
Isoniazid, 109, 329
Isoproterenol, 249

Kappa receptor, 125, 129
Ketamine, 399
Kindling, 893
Kitanserin, 1009

Lateral hypothalamus, 323
Learning, 79
Learning and memory, 949
Lesioning, 923
Lever-press, 875
Ligand binding, 461, 471
Ligands, 1009
Light/dark test, 733, 739
Lithium, 983
Lithium chloride, 717
Liver, 533
Liver microsomes, 541
Locomotion, 169
Locomotor activity, 21, 121, 215, 255, 381, 399, 423, 509, 811, 841, 881, 941
Locomotor balance, 367
Locomotor response, 181
Long-sleep and short-sleep mice, 941
Long-term effects, 683
Long-term memory, 173
Long-term potentiation, 893
Lorazepam, 429
Lung, 637, 663
Lung injury, 629

Macrophage morphology, 643
Macrophage protein, 643
Macrophages, 663
Male and female rats, 901
Male rat, 443
Man, 523
Mapping, 351
Marihuana, 513, 609
Marijuana, 97, 487, 517, 571, 629, 637, 651, 657, 663, 671, 701
Marijuana smoke, 677
Masculine behavior, 221
Mass spectrometry, 523, 533
Matching-to-sample, 417
Maximal electroshock seizures, 109
Mazindol, 941
MDMA, 433, 915
Meals, 867
Membrane interaction, 547
Memory, 1, 79
Memory impairment, 701
Memory modulation, 417
Menstrual, 995
5-MeODMT, 311
Mesencephalic central gray area, 323
Mesolimbic reward system, 923
Metabolites, 487
Met-enkephalin, 449
Methylatropine, 745
N-Methyl-D-aspartate, 767
5-Methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK-801), 767
Methylenedioxymethamphetamine, 443
Methyl naltrexone, 771
Methylphenidate, 757, 775
Methylphenidate enantiomers, 875
Methylxanthine, 847
Methylxanthine-benzodiazepine interaction, 723
Mice, 65, 261, 279, 581, 767, 847
Microdialysis, 387, 571, 587
Microfilaments, 617
Microinjection, 33
Microphotometry system, 423
Microsomes, 533
Microtubules, 617
Midazolam and caffeine complications, 723
Midazolam pharmacokinetics, 723
MK-801, 21, 291, 893, 949
Molecular biology, 1053
Molecular modeling, 471, 1019, 1033
Molecular orientation, 553
Monkey brain, 677
Monkeys, 671
Monoamine oxidase, 359, 751
Monoamine oxidase inhibitors, 915
Monoamines, 409
Mood, 229
Morphine, 21, 27, 283, 317, 771, 819, 887
Morphology, 637
Morphometry, 671
Motion sickness, 345
Motor activity, 103
Motor behavior, 305, 763
Motor cortex, 351
Motor incoordination, 465
Mouse, 103, 323, 399, 533
Mouse lines, 283
Mouse peritoneal cells, 559
Multiple schedule, 41, 775
Muscarinic, 763
Muscarinic cholinergic receptor, 677
Muscarinic receptor subtypes, 345
Myorelaxation, 261

NA, 7
Naloxone, 283, 297, 323, 339, 819, 887
Naltrexone, 79, 185, 443, 771, 807
Neck muscle activity, 367
Negative contrast, 433
Neonatal, 291
Neonatal mice, 241
Neostriatal dopamine, 423
Neuroblastoma cells, 565
Neuroleptics, 1001
Neurological disease, 701
Neuronal plasticity, 893
Neuropeptide-Y, 417
Neurotoxic effects, 241
Neurotoxicity, 915
Neurotoxicology, 671
Neurotoxins, 923
Never-smokers, 995
Nicotine, 53, 121, 177, 203, 229, 453, 995
Nicotine compensation, 139
NMDA, 841
NMDA antagonist, 291
NMDA receptor, 893
Nociception, 197
(−)-11-Nor-Δ^9-tetrahydrocannabinol-9-carboxylic acid, 487
Noradrenaline, 173
α-Noradrenergic receptors, 853
Norepinephrine, 241, 853
NPY, 417
Nucleus accumbens, 21, 181, 399, 841, 923, 959, 969

Obesity, 853
Object recognition, 7
Obsessive-compulsive disorder, 311
Odor preference, 781
Ofloxacin, 65
8-OH-DPAT, 221, 311, 739, 1009
Olfactory cortex, 351
Olfactory discrimination, 241
Olfactory lobe, 241
Ondansetron (GR38032F), 739
Ontogeny, 811, 829
Open field, 7
Operant, 835
Operant behavior, 745
Operant responses, 249
Opiate, 771, 819
Opiate antagonist, 79
Opiate receptor, 887
Opioid, 129, 297, 571, 819
Opioid antagonist, 5, 185
Opioid systems, 807
Optical purity, 491
Oral administration, 517, 701
Orgasm, 151
Oxidants, 663
Oxytocin, 27, 261

Pain, 283
Palliative care, 695
Panic disorder, 723
Paraoxon, 929
Paraventricular nucleus, 853
Pathology, 637
PCPA, 433
Penicillin, 351
Pentobarbital, 767, 801
Pentylenetetrazol, 109, 297, 329
Pentylenetetrazole, 581, 987
Perinatal, 847
Peripheral nerve injury, 301
Peripheral-type benzodiazepine receptors, 409
PET, 503
Phantom limb pain, 301
Pharmacokinetics of CBD, 517
Pharmacophore, 1033
Pharmacotoxicity, 465
Phencyclidine, 381, 767
Phenoxybenzamine, 399
Phentolamine, 709
2-Phenylaminoadenosine (CV-1808), 33
N-Phenylbiguanide, 739
Phenylisopropyladenosine, 811
Phospholipase A_2, 609
Phospholipases, 559
Physical activity, 203
Physical dependence, 801
Picrotoxin, 21, 329
Pig, 17
Pigeons, 41
Pimozide, 317
Piracetam, 1
Placebo, 517, 701
Plasma cotinine, 139, 907
Plasma delta-1-tetrahydrocannabinol, 517
Plasma delta-9-THC, 517
Plasma levels of CBD, 517, 701
Plasma nicotine, 139, 907
Plasma testosterone, 287
Posture, 367
Predictability, 787, 795
Premature ejaculation, 221
Prenatal, 599

Prenatal administration, 191
Prenatal exposure, 429
Prenatal nicotine, 991
Preoptic area, 33
Prepartum, 847
Pressure reversal, 197
Presynaptic, 571
Preweanling, 291
Primary sequence, 1053
Primates, 637
Proactive interference, 417
Proconflict, 787
Prolactin, 603
Propranolol, 399
Proton NMR, 491
Psychogenetic selection, 7
Psychomotor performance, 723
Psychomotor stimulant, 775, 959
Psychopharmacological activity, 479
Puffing behavior, 177
Puffing topography, 139, 907
Pulmonary alveolar macrophages, 629
Pulmonary function tests, 663
Pulmonary resistance, 17
Pulse rate, 701
Pyridostigmine, 17, 745
Pyrilamine, 433

Quinine, 209
Quinpirole, 317

Rabbit, 533
Raclopride, 133, 209
Radial maze, 7
Radioligand binding, 345
Rat, 1, 33, 75, 83, 121, 125, 133, 197, 209, 339, 417, 453, 523, 533, 599, 671, 709, 717, 745, 757, 775, 801, 829, 875, 983, 987
Rat brain, 677
Rat testis, 625
Rearing behavior, 959
Receptor, 83, 941, 1019
Receptor blockers, 237
Receptor models, 1019
Rectal temperature, 509
Reference memory, 417
Reinforcement, 41, 229, 571, 959, 1001
Release, 571
Reproductive system, 599
Respiratory carbon monoxide, 139, 907
Response requirements, 273
Retest reliability, 139
Retrieval, 1
Reward, 443, 571
Ring immobility, 509
RNA synthesis, 603
RO40-2148, 249
Roman strains of rats, 7
Runway, 125

S49 Lymphocytes, 559
Saccharin, 209, 717
Safety, 701
Salt appetite, 163, 977
SCH 23390, 133, 157, 317, 829
Schedule-controlled behavior, 875, 929
Scopolamine, 21
Sea urchin, 609
Secalonic acid D, 241
Second messenger systems, 1053
Sedation, 79, 335
Seizure threshold, 359
Selective attention, 683
Selective breeding, 283
Self injury, 79
Self-administration, 41, 807
Self-induced nonequivalence, 491
Self-stimulation, 273, 571
Seminal plugs, 443
Sensory-specific satiety, 185
Serotonin, 83, 151, 311, 433, 733, 739, 901, 915, 959, 969, 1001, 1019, 1033, 1041
Serotonin$_3$, 83
Serotonin receptors, 1009, 1053
Serotonin$_{1A}$ receptors, 1041
Serotonin reuptake, 923
Sertraline, 923
Sesame oil, 701
Sesame oil vehicle, 517
Sex differences, 819
Sexual arousal, 287
Sexual attractivity, 221
Sexual behavior, 221
Sexual climax, 151
Shock-induced fighting, 69
Short-term memory, 417
SHR, 157
Side effects, 701
SKF 38393, 317
Sleep, 33
Sleep latency, 65
Sleeping time, 65
Smoke absorption, 139
Smoke exposure, 907
Smokers, 203, 995
Smoking, 177, 229, 637, 663
Smoking cessation, 937
Smoking profile, 651
Social attraction, 781
Sodium excretion, 163
Sodium pentobarbital, 65
Solid state NMR, 553
Spatial memory and sex differences, 991
Species difference, 541
Sperm, 609
Spontaneous alternation, 311
Spontaneous firing rate restoration, 367
Staircase Test, 7
Stereospecificity, 461
Stereotyped behaviour, 191
Stereotypy, 381
Steroid receptors, 861
Stress, 197, 297, 763
Striatum, 7, 305, 587, 829
Structure-activity relationship, 479, 1033, 1041
Subjective effects, 115, 691
Submandibular gland, 345
Successive, 433
Sucrose, 209, 983
Sulpiride, 157
Superior colliculus, 215
Supportive care, 695
Suppositories, 497
Sweet taste, 995
Swim stress, 409
Swim-induced analgesia, 283
Swimming, 241
Symptoms, 701
Synaptic loss, 367
Synaptic plasma membrane, 547
Synaptic reoccupation, 367
Tachykinins, 977
Tail-tremor, 453
Tar, 651, 657
Tetrahydrocannabinoid, 491
Tetrahydrocannabinol, 115, 533, 547, 553
Δ-Tetrahydrocannabinol, 571
Δ^1-Tetrahydrocannbinol, 559
Δ^9-Tetrahydrocannabinol, 657
THC, 513, 571, 587, 599, 625, 671, 695
Δ^9-THC, 571
THC esters, 497
THC infusion, 691
THC plasma levels, 691
Therapeutic effects, 701
Thermoregulatory behavior, 249
Thiosemicarbazide, 287
Thirst, 867
Three-bottle test, 209
Three-dimensional, 1033
Tissue glutathione, 513
Tobacco, 629, 663, 937
Tolerance, 97, 121, 283, 887
Toxicity, 513, 701
Trachea, 345
Training stimulus intensity, 173
Transmitters, 61
Triadimefon, 757, 775
Triazolam, 835
Triazole, 775
(−)-5′-Trifluoromethyl-Δ^8-THC, 509
Triggering, 173
Tryptophan, 301
Tryptophan hydroxylase, 751
Tubulin, 617
Tunicamycin, 565
Tunnel maze, 121
Two-bottle test, 209
Tylenol, 513
Tyrosine hydroxylase, 593

U50,488H, 125, 129
Umespirone, 89
Uncontrollable shock, 69
Urethra, 151
Urination, 443
Urine, 523
Urine volume, 163

Vasopressin, 27
Ventilation blocking, 907
Ventral hippocampus, 169
Vervet monkey, 267
Vestibular compensation, 367
Vestibular nuclei, 367
Vestibulo-collic reflex, 367
Visual perception, 689
Voltammetry, 305, 571

Water intake, 133
Whole blood srotonin, 267
Wistar rat, 221
Withdrawal, 937
Working memory, 7, 417

X-ray diffraction, 547

Yohimbine, 781

Zacopride, 733
Zucker rats, 853

AUTHOR INDEX

Abbott, F. V., 301
Abraini, J. H., 305
Adler, M. W., 129
Ahlers, S. T., 417
Ahmad, M., 847
Ahmed, K. M., 513
Airaksinen, M. M., 177
Ajarem, J. S., 847
Akiyama, K., 423
Akunne, H. C., 387
Ali, S. F., 637, 643, 677
Allen, A. R., 775
Allender, J., 701
Antelman, S. M., 53
Anwer, J., 625
Araki, Y., 453
Asin, K. E., 1001
Audette, C. A., 559
Avgustinovich, D. F., 751
Awad, I. R., 853

Bacciarelli, C., 163
Baek, S.-H., 487
Bailey, J. R., 637, 643, 677
Banijamali, A. R., 509, 553
Banks, W. A., 771
Bardelay, C., 7
Bardo, M. T., 829
Barnes, N. M., 89
Barron, J. L., 79
Bartke, A., 593
Bättig, K., 121, 139, 907
Beals, T. F., 637
Behrens, M., 781
Bemis, K. G., 103
Berge, O.-G., 197
Berkery, D., 609
Bernardi, M., 191
Beverly, J. L., III, 83
Bidzseranova, A., 61, 237
Bilsky, E. J., 443
Blanchard, D. C., 819
Blanchard, R. J., 819
Blass, E., 185
Bliss, R. E., 937
Bradley, E., 129
Brammer, G. L., 267
Breese, G. R., 875
Bresnahan, E. L., 949
Breuer, A., 461
Bridger, W. H., 311
Britton, K. T., 717
Broderick, P. A., 959, 969
Broderick, W., 547
Brown, N. K., 533
Browne, S. E., 581
Bruhwyler, J., 1
Bryda, M., 785
Burstein, S. H., 559

Cabral, G. A., 643
Caggiula, A. R., 53
Calcagnetti, D. J., 255
Caldarola-Pastuszka, M., 901
Camí, J., 115
Campbell, A. D., 941
Carboni, G., 329
Carlisle, H. J., 249
Carlson, J. N., 781, 785
Carr, R. L., 929
Carver, E. S., 157
Castañeda, E., 587
Cazala, P., 323
Chambers, J. E., 929
Champion-Dorow, T. M., 565
Chang, M. C., 609
Chang, P., 651, 657
Charalambous, A., 503, 509, 553
Chávez, D., 603
Chee, S.-J., 215
Chen, K., 1053
Cheng, Y., 97
Cherek, D. R., 835
Chesley, S., 429
Chiavegatto, S., 191
Chleide, E., 1
Ciccocioppo, R., 163
Cohen, C., 121
Compton, D. R., 471, 479, 509
Consroe, P., 517, 701
Cook, C. E., 691
Corda, M. G., 329
Costall, B., 89
Costello, N. L., 781, 785
Cowan, K. A., 835
Croix, D., 599
Crowe S. F., 173
Cuadra, G. R., 69

Daniell, L. C., 767
David, V., 323
De Caro, G., 163, 977
de Castro, J. M., 867
Decena, J. A., 97
de Costa, B. R., 387
Delacour, J., 7
De La Torre, R., 115
Delconte, J. D., 443
de Lima, T. C. M., 297
Devane, W. A., 461
Dewey, S. L., 503
Dhali, J., 603
Diamantis, W., 109
Dib, B., 449
Dilsaver, S. C., 763
Domeney, A. M., 89
Donoso, A. O., 335
Dormer, K. N., 987
Doyle, S. A., 559
Drewnowski, A., 995
Drucker, G. E., 881
Dukat, M., 1009

Eckerman, D. A., 757, 875
Eldridge, J. C., 593
Elsohly, M. A., 497
Emrich, H. M., 689
Engh, K., 881
Enginar, N., 65
Epstein, L. H., 53, 203
Eroğlu, L., 65
Erwin, V. G., 941
Esseling, K., 351
Evans, S. M., 1033
Ez-Zaher, L., 367

Falk, J. L., 723
Fernández-Ruiz, J. J., 593
Fields, J. Z., 881
Finkelstein, J. A., 853
First, M. W., 629
Flaherty, C. F., 433
Fligiel, S. E. G., 637
Fournier, D., 547
Fox, A. M., 683
Frances, H., 279
Frank, R. A., 273
Franklin, K. B. J., 317
Frau, V., 329
Friedman, E., 311
Friend, F. L., 509
Fuller, S. A., 339
Furset, K., 197
Furuno, K., 453

Galdes, A., 1033
Gall, M., 1033
Gallaher, T., 1053
Galpern, W. R., 429
Garcia, A. W., 995
Garcia-Cabrera, I., 197
Gardner, E. L., 571
Gargiulo, P. A., 335
Garofalo, P., 949
Garvey, A. J., 937
Gauvin, D. V., 987
Gearhart, G. M., 853
Geller, E. B., 129, 267
Gels, M., 109
Gerrard, P. A., 89
Gibbs, M. E., 173
Gibson, B. M., 781
Gietzen, D. W., 83
Gilbert, D. G., 229
Giorgi, O., 329
Glennon, R. A., 1009, 1019
Glick, S. D., 781, 785
Gliederer, F., 651, 657
Gohda, H., 541
Gómez, M. A., 887
Gomita, Y., 453
Gong, H., Jr., 663
Goodwin, G. A., 291
Gordon, J. H., 881
Gordon, R., 109
Gorter, R. W., 695
Graziani, M., 125
Greenblatt, D. J., 429
Greig, N., 387
Grigson, P. S., 433
Grubner, O., 629
Gueron, J., 61
Guerra, D., 115
Guillet, R., 811
Gulati, K., 27

Haensel, S. M., 221
Halldin, M. M., 487
Hanisch, W., 689
Harland, E., 497
Harvey, D. J., 523, 533
Hasegawa, T., 359
Hashimoto, H., 359
Heinrichs, S. C., 717
Heller, B., 949
Hetherington, M. M., 185
Hetrick, W. P., 79
Hicks, R. E., 691
Hikal, A., 497
Ho, I. K., 157
Höfer, I., 139, 907
Hoh, J., 763
Holloway, F. A., 987
Horn, E., 351
Hoskins, B., 157
Howlett, A. C., 565
Hrupka, B. J., 83
Huang, X., 915
Hubbell, C. L., 443
Huber, G. L., 629
Hui, K. K., 651, 657
Hui, R. A. H. F., 491
Hunter, S. A., 559
Hurd, M., 709
Husain, S., 513, 625

Ingram, D. K., 949
Inoue, K., 893
Irifune, M., 399
Ishizuka, Y., 157

Jacob, R. G., 203
Jaeckle, R. S., 763
Jaffe, J. H., 381
Jaskiw, G. E., 169, 181
Jeffcoat, A. R., 691
Jhanwar-Uniyal, M., 853
Jodogne, C., 261
Johnson, D. N., 733, 739
Johnson, M. P., 915
Johnson, M. R., 471
Jones, B. C., 941

Karoum, F., 181
Kastin, A. J., 771
Katayama, K., 893
Kellogg, C. K., 811
Kelly, M. E., 89
Kemble, E. D., 781
Kennedy, K., 517, 701
Kent, S., 709
Kim, T., 861
Kleinman, J. E., 181
Klingbiel, P., 261
Knight, K. C., 151
Knopf, S., 53
Kobayashi, H., 465
Kolonen, S., 177
Koob, G. F., 717, 841
Korpi, E. R., 409
Krähling, H., 89

Krasnow, S. H., 695
Kulikov, A. V., 751
Kyprianou, T., 209

Lacour, M., 367
Laguna, J., 701
Landsberg, L., 937
Lane, M., 695
Lau, C. E., 723
Laughton, W. B., 75
Layer, R. T., 21
Lecca, D., 329
Legros, J. J., 261
Leibowitz, S. F., 853, 861
Leonardelli, J., 599
Lin, S., 509
Lipska, B. K., 169, 181
Little, P. J., 471
Little, T. L., Jr., 497
Liu, W.-F., 745
Lowinson, J. H., 571
Lucot, J. B., 345

McDonald, S. A., 691
McGaughey, G. B., 479
McGuire, M. T., 267
McKenna, K. E., 151
McMahon, L. L., 565

MacLeod, K. B., 983
MacPhail, R. C., 757, 775
Makriyannis, A., 503, 509, 547, 553
Manderscheid, P. Z., 273
Manzini, S., 163
Marciniak, G., 503, 509, 553
Marek, P., 283
Martin, B. R., 471, 479, 509
Martinez, R., 129
Massi, M., 163, 977
Matsunaga, T., 465
Mavromoustakos, T., 547
Mayers, R., 151
Mechoulam, R., 461, 471, 523
Mele, A., 387
Meliska, C. J., 229
Melvin, L. S., 471
Mercier, M., 1
M'Harzi, M., 7
Michie, P. T., 683
Miller, L. G., 429
Modell, H. I., 17
Molina, V. A., 69
Monier, C., 279
Montella, P. G., 241
Morgan, M. J., 317
Morimoto, K., 893
Mos, J., 221
Moss, D. E., 587
Moy, S. S., 875
Murphy, L. L., 593, 603
Muscat, R., 209
Muth, N. J., 949
Myers, R. D., 923

Nakajima, T., 359
Nakao, J., 359
Narimatsu, S., 541
Naumenko, E. V., 287
Naylor, R. J., 89
Nelson, D. L., 1041
Nelson, D., 75
Nencini, P., 125
Neri, C. L., 79
Newport, G. D., 677
Newton, S. C., 603
Ng, K. T., 173
Nichols, D. E., 915
Nil, R., 139, 907
Nomoto, M., 399
Noto, T., 359

Oddie, S. D., 587
Odear, D. F., 479
Olivier, B., 221
Orlandi, M., 329
Orozco, S., 867
Osman, M., 209

Panerai, A. E., 449
Panocka, I., 283
Parker, L. A., 983
Patrick, K. S., 875
Paule, M. G., 637, 643, 677
Pearson, M. A., 771
Peck, J. A., 763
Pedigo, N. W., Jr., 829
Penke, B., 61
Perez-Reyes, M., 691
Perfumi, M., 163
Perkins, A. N., 757, 875
Perkins, K. A., 53, 203
Pert, A., 387
Pertwee, R. G., 581
Peters, S. C., 103
Phillips, G., 209
Phillips, I., 181
Plasse, T. F., 695
Polidori, C., 163
Pomerleau, C. S., 995
Pomerleau, O. F., 995
Pompei, P., 977
Popova, N. K., 751
Prescott, W. R., 471
Pulvirenti, L., 841
Puustinen, P., 177

Quarfordt, S. D., 923

Radcliffe, R. A., 941
Radulovacki, M., 33
Rae, G. A., 297
Rajachandran, L., 291
Raleigh, M. J., 267
Ramsey, N. F., 807
Rapoza, D., 133
Raskin, L. A., 991
Rawleigh, J. M., 781
Ray, A., 27
Raymond, J., 367
Razdan, R. K., 471
Reddy, C. S., 241
Reggio, P. H., 479
Reid, A. A., 387
Reid, L. D., 443
Reynen, M., 801
Rice, K. C., 387
Ritvo, E. R., 267
Roache, J. D., 835
Rockhold, R. W., 157
Rodgers, R. J., 819
Rodríguez de Fonseca, F., 593
Rolls, B. J., 185
Rose, J., 651, 657
Ross, T. M., 581
Rostain, J. C., 305
Roth, M. D., 663
Rothman, R. B., 387
Rowlett, J. K., 829

Sacerdote, P., 449
Sadowski, B., 283
Salabarria, J., 75
Salamanca, S., 901
Salamone, S., 491
Samara, E., 523
Sandman, C. A., 79
Sandyk, R., 701
Satinoff, E., 709
Sato, K., 893
Saylor, S. S., 53
Scallet, A. C., 637, 643, 671, 677
Schechter, M. D., 255
Schlyer, D. J., 503
Schram, K., 517, 701
Schuel, H., 609
Schuel, R., 609
Schulkin, J., 977
Schwartz, M., 273
Segura, J., 115
Seltzman, H. H., 479
Serova, L. I., 287
Sexton, J. E., 203
Shader, R. I., 429
Shannon, H. E., 103
Sharma, K. K., 27
Sharpe, L. G., 381
Shepard, J., 819
Shepard, K. V., 695
Sherman, M. P., 663
Shih, J. C., 1053
Shimizu, T., 399
Shiue, C.-Y., 503
Slikker, W., Jr., 637, 643, 677
Slob, A. K., 221
Snider, S., 701
Sofia, R. D., 109
Solowij, N., 683
Sorenson, C. A., 991
Spangler, E. L., 949
Sparrow, D., 937
Spear, L. P., 291
Spiga, R., 835
Stanford, D. F., 497
Steger, R. W., 593
Stein, E. A., 339
Stern, L., 701
Stiller, R. L., 53, 203
Stinnett, A. L., 643
Stock, M. J., 249
Stretton, C. D., 581
Suemaru, K., 453
Suh, Y., 991
Sutoo, D., 423
Swerdlow, N. R., 841
Székely, J. I., 381
Szeto, H. H., 97
Szirmai, M., 487

Tahir, S. K., 617
Takita, H., 423
Tashkin, D. P., 637, 651, 657, 663
Tayebaty, J., 977
Taylor, D. V., 79
Telegdy, G., 61, 237
Tempel, D. L., 861
Thomas, B. F., 471
Thomas, J. R., 417
Thompson, D. M., 41
Thurkauf, A., 387
Ticho, S. R., 33
Tirelli, E., 261
Tomkins, D. M., 89
Toth, G., 237
Touchette, P., 79
Tramu, G., 599
Tulp, M. Th. M., 345
Tuominen, K., 409
Tuomisto, J., 177

Ugena, B., 115
Ulak, G., 65
Uphouse, L., 901
Uretsky, N. J., 21

Valeri, P., 125
van Charldorp, K. J., 345
van Ree, J. M., 807
Vervaet, N., 185
Viet, D., 7
Voitenko, N. N., 751
Von Meyer, L., 689

Wadleigh, R. G., 695
Wagner, R., 351
Walker, L., 497
Wallace, L. J., 21
Ward, K. D., 937
Ward, S. J., 471
Watanabe, K., 465, 541
Weatherford, S. C., 75
Weatherspoon, A., 819
Weber, M. M., 689
Weinberger, D. R., 169, 181
Weiss, S. M., 819
Welzl, H., 121
Wendl, A., 689
Wenger, T., 599
Westkaemper, R. B., 1019
Westlake, T. M., 565
Whishaw, I. Q., 587
White, W. R., 691
Wichlinski, L., 881
Williams, H. P., 273
Williams, T. H., 491
Williams, T. J., 89
Willig, F., 7
Willner, P., 209
Winsauer, P. J., 41
Wirtshafter, D., 1001
Wolf, A. P., 503
Woolverton, W. L., 133
Wu, D.-L., 97
Wu, T.-C., 651, 657

Yadin, E., 311
Yamamoto, I., 465, 541
Yamamoto, M., 861
Yang, D.-P., 547, 553

Yang, W., 1053
Yoshimura, H., 465, 541
Young, J. B., 937
Young, R., 733, 739
Young, S. N., 301
Yu, J. L., 651, 657
Yutrzenka, G. J., 801
Yuwiler, A., 267
Zabala, N. A., 887
Zahalka, J., 461
Zihl, J., 689
Zimmerman, A. M., 609, 617
Zimmerman, S., 609